| . | Japanese ITT . | PD-L1 positive . | ||
|---|---|---|---|---|
| . | Atezolizumab + nab-paclitaxel (n = 34) . | Placebo + nab-paclitaxel (n = 31) . | Atezolizumab + nab-paclitaxel (n = 12) . | Placebo + nab-paclitaxel (n = 13) . |
| Objective confirmed response, n (%) | ||||
| Objective response (95% CI) | 23 (67.6) (49.5–82.6) | 16 (51.6) (33.1–69.9) | 9 (75.0) (42.8–94.5) | 7 (53.8) (25.1–80.8) |
| Complete response | 1 (2.9) | 0 | 0 | 0 |
| Partial response | 22 (64.7) | 16 (51.6) | 9 (75.0) | 7 (53.8) |
| Stable disease | 9 (26.5) | 11 (35.5) | 2 (16.7) | 5 (38.5) |
| Progressive disease | 2 (5.9) | 3 (9.7) | 1 (8.3) | 1 (7.7) |
| Missing or unevaluable | 0 | 1 (3.2) | 0 | 0 |
| Duration of responsea | ||||
| Median (95% CI), months | 5.6 (3.7–9.1) | 3.7 (3.6–5.6) | 9.1 (7.3–NE) | 3.7 (1.9–5.5) |
| . | Japanese ITT . | PD-L1 positive . | ||
|---|---|---|---|---|
| . | Atezolizumab + nab-paclitaxel (n = 34) . | Placebo + nab-paclitaxel (n = 31) . | Atezolizumab + nab-paclitaxel (n = 12) . | Placebo + nab-paclitaxel (n = 13) . |
| Objective confirmed response, n (%) | ||||
| Objective response (95% CI) | 23 (67.6) (49.5–82.6) | 16 (51.6) (33.1–69.9) | 9 (75.0) (42.8–94.5) | 7 (53.8) (25.1–80.8) |
| Complete response | 1 (2.9) | 0 | 0 | 0 |
| Partial response | 22 (64.7) | 16 (51.6) | 9 (75.0) | 7 (53.8) |
| Stable disease | 9 (26.5) | 11 (35.5) | 2 (16.7) | 5 (38.5) |
| Progressive disease | 2 (5.9) | 3 (9.7) | 1 (8.3) | 1 (7.7) |
| Missing or unevaluable | 0 | 1 (3.2) | 0 | 0 |
| Duration of responsea | ||||
| Median (95% CI), months | 5.6 (3.7–9.1) | 3.7 (3.6–5.6) | 9.1 (7.3–NE) | 3.7 (1.9–5.5) |
ITT, intention-to-treat; PD-L1, programmed death-ligand 1.
aInvestigator assessed.
| . | Japanese ITT . | PD-L1 positive . | ||
|---|---|---|---|---|
| . | Atezolizumab + nab-paclitaxel (n = 34) . | Placebo + nab-paclitaxel (n = 31) . | Atezolizumab + nab-paclitaxel (n = 12) . | Placebo + nab-paclitaxel (n = 13) . |
| Objective confirmed response, n (%) | ||||
| Objective response (95% CI) | 23 (67.6) (49.5–82.6) | 16 (51.6) (33.1–69.9) | 9 (75.0) (42.8–94.5) | 7 (53.8) (25.1–80.8) |
| Complete response | 1 (2.9) | 0 | 0 | 0 |
| Partial response | 22 (64.7) | 16 (51.6) | 9 (75.0) | 7 (53.8) |
| Stable disease | 9 (26.5) | 11 (35.5) | 2 (16.7) | 5 (38.5) |
| Progressive disease | 2 (5.9) | 3 (9.7) | 1 (8.3) | 1 (7.7) |
| Missing or unevaluable | 0 | 1 (3.2) | 0 | 0 |
| Duration of responsea | ||||
| Median (95% CI), months | 5.6 (3.7–9.1) | 3.7 (3.6–5.6) | 9.1 (7.3–NE) | 3.7 (1.9–5.5) |
| . | Japanese ITT . | PD-L1 positive . | ||
|---|---|---|---|---|
| . | Atezolizumab + nab-paclitaxel (n = 34) . | Placebo + nab-paclitaxel (n = 31) . | Atezolizumab + nab-paclitaxel (n = 12) . | Placebo + nab-paclitaxel (n = 13) . |
| Objective confirmed response, n (%) | ||||
| Objective response (95% CI) | 23 (67.6) (49.5–82.6) | 16 (51.6) (33.1–69.9) | 9 (75.0) (42.8–94.5) | 7 (53.8) (25.1–80.8) |
| Complete response | 1 (2.9) | 0 | 0 | 0 |
| Partial response | 22 (64.7) | 16 (51.6) | 9 (75.0) | 7 (53.8) |
| Stable disease | 9 (26.5) | 11 (35.5) | 2 (16.7) | 5 (38.5) |
| Progressive disease | 2 (5.9) | 3 (9.7) | 1 (8.3) | 1 (7.7) |
| Missing or unevaluable | 0 | 1 (3.2) | 0 | 0 |
| Duration of responsea | ||||
| Median (95% CI), months | 5.6 (3.7–9.1) | 3.7 (3.6–5.6) | 9.1 (7.3–NE) | 3.7 (1.9–5.5) |
ITT, intention-to-treat; PD-L1, programmed death-ligand 1.
aInvestigator assessed.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
